Validation of a Molecular Prognostic Test for Eye Melanoma

Withdrawn before enrolling

Conditions studied: Uveal Neoplasms, Choroid Neoplasms, Iris Neoplasms

In brief

Up to half of patients with ocular melanoma (also called iris, choroidal or uveal melanoma) develop metastasis. We have found that certain molecular features of the eye tumor can be detected by gene expression profiling and accurately predict which patients will develop metastasis. This molecular test could eventually allow high risk patients to receive preventative therapy to delay or prevent the development of metastasis. The goal of this study is to prospectively validate the predictive accuracy of the gene expression-based molecular test and compare it to monosomy 3, the most common but potentially less accurate molecular marker for metastasis in ocular melanoma.

Key facts

Study ID

NCT00406120

Run by

Washington University School of Medicine

People needed

0

Starts

2007-05-01

Expected to finish

2010-05-01

Last updated by the study team

2018-06-26

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• clinical diagnosis of melanoma of the iris, ciliary body and/or choroid
• treatment to include enucleation, radiotherapy or local tumor resection

You may not qualify if…

• evidence of marked tumor necrosis

Where it is running

• Washington University School of Medicine — St Louis, Missouri, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.